Full Press Release Details
Nutriband Inc. Signs Agreement to Sell Majority
Pocono Pharmaceutical for $5M USD to EarthVision Bio
Earthvision Bio, is currently developing and commercializing its line
of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke,
ex-chairman for Chevron Europe
Nutriband Inc. Shareholders will
retain 10% of the shareholding in Earth Vision Bio following the acquisition
The expected closing date for
the transaction is Dec 31, 2025.
Orlando, Fla. - Dec 29, 2025 - Nutriband Inc. (NASDAQ:
NTRB) (NASDAQ: NTRBW), today announced that it has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical
for $5M USD to EarthVision Bio.
Earthvision Bio has developed
and are commercializing a new category of sustainable products created by Dr. Gordon Moore, the founder of Intel (NASDAQ: INTC), and Dr.
Hans Franke, who was board chairman for Chevron Europe. The Company has developed a sustainable way to replace plastic, molded fiber,
wood, and paper products with Earth-friendly alternatives.
Nutriband Inc. Shareholders will
retain 10% of the shareholding in Earth Vision Bio following the acquisition.
Nutriband inc. will use the proceeds
from the sale of Pocono Pharma towards its continued development of AVERSA Fentanyl which has the potential to be the world's first and
only abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl
patches. AVERSA Fentanyl has the potential to reach annual US sales of $80 million to $200 million.
About AVERSA Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA abuse-deterrent transdermal technology incorporates
aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.
The AVERSA abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse,
including opioids and stimulant drugs, while making sure that these drugs remain accessible to those patients who really need them. The
technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia,
China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal
pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA abuse-deterrent
technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental
exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained
Forward-Looking Statements
Certain statements contained in this press release, including, without
limitation, statements containing the words "believes," "anticipates," "expects" and words of similar
import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially
from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability
to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection
for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing,
its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain
any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market
any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel;
changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international,
national and local general economic and market conditions and risks generally associated with an undercapitalized developing company,
as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and
Results of Operations" in the Company's periodic and current reports on Form 10-K, Forms 10-Q and 8-K and the Company's other filings
with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any
forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Email: info@nutriband.com
Email: Tina@earthvisionbio.com
SOURCE: Nutriband Inc.